PH12019501973A1 - Anti-phf-tau antibodies and uses thereof - Google Patents
Anti-phf-tau antibodies and uses thereofInfo
- Publication number
- PH12019501973A1 PH12019501973A1 PH12019501973A PH12019501973A PH12019501973A1 PH 12019501973 A1 PH12019501973 A1 PH 12019501973A1 PH 12019501973 A PH12019501973 A PH 12019501973A PH 12019501973 A PH12019501973 A PH 12019501973A PH 12019501973 A1 PH12019501973 A1 PH 12019501973A1
- Authority
- PH
- Philippines
- Prior art keywords
- antibodies
- phf
- tau antibodies
- tau
- tauopathies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7047—Fibrils-Filaments-Plaque formation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762472214P | 2017-03-16 | 2017-03-16 | |
| PCT/US2018/022782 WO2018170351A1 (en) | 2017-03-16 | 2018-03-16 | Anti-phf-tau antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12019501973A1 true PH12019501973A1 (en) | 2020-06-29 |
Family
ID=63521020
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH12019501973A PH12019501973A1 (en) | 2017-03-16 | 2019-08-28 | Anti-phf-tau antibodies and uses thereof |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US10766953B2 (https=) |
| EP (1) | EP3596119A4 (https=) |
| JP (3) | JP7159185B2 (https=) |
| KR (2) | KR102695287B1 (https=) |
| CN (2) | CN117209599A (https=) |
| AR (1) | AR111288A1 (https=) |
| AU (1) | AU2018234709B2 (https=) |
| CA (1) | CA3055598A1 (https=) |
| CL (1) | CL2019002566A1 (https=) |
| EA (1) | EA201992038A1 (https=) |
| IL (2) | IL268700B2 (https=) |
| JO (1) | JOP20180021A1 (https=) |
| MA (1) | MA47789A (https=) |
| MX (2) | MX2019010922A (https=) |
| MY (1) | MY205672A (https=) |
| PH (1) | PH12019501973A1 (https=) |
| SG (1) | SG11201907754RA (https=) |
| TW (1) | TWI771389B (https=) |
| UA (1) | UA128385C2 (https=) |
| UY (2) | UY37635A (https=) |
| WO (1) | WO2018170351A1 (https=) |
| ZA (2) | ZA202101318B (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX350311B (es) * | 2011-12-20 | 2017-09-01 | Janssen Biotech Inc | Anticuerpos anti-phf-tau y sus usos. |
| US10501531B2 (en) | 2013-03-13 | 2019-12-10 | Prothena Biosciences Limited | Tau immunotherapy |
| PT3452507T (pt) | 2016-05-02 | 2022-12-20 | Prothena Biosciences Ltd | Imunoterapia anti-tau |
| MY198194A (en) | 2016-05-02 | 2023-08-09 | Prothena Biosciences Ltd | Antibodies Recognizing Tau |
| SG11201907422RA (en) | 2017-02-17 | 2019-09-27 | Denali Therapeutics Inc | Anti-tau antibodies and methods of use thereof |
| KR102784294B1 (ko) | 2017-05-02 | 2025-03-19 | 프로테나 바이오사이언시즈 리미티드 | 타우 인식 항체 |
| AU2018352308B2 (en) | 2017-10-16 | 2025-06-05 | Eisai R&D Management Co., Ltd. | Anti-tau antibodies and uses thereof |
| CA3093200A1 (en) | 2018-03-05 | 2019-09-12 | Janssen Pharmaceutica Nv | Anti-phf-tau antibodies and uses thereof |
| JP7630834B2 (ja) | 2019-03-03 | 2025-02-18 | プロセナ バイオサイエンシーズ リミテッド | タウ認識抗体 |
| KR102905634B1 (ko) * | 2019-05-31 | 2025-12-30 | 일라이 릴리 앤드 캄파니 | 인간 타우를 표적화하는 화합물 및 방법 |
| JP7181438B2 (ja) * | 2019-08-06 | 2022-11-30 | アプリノイア セラピューティクス リミテッド | 病理学的タウ種に結合する抗体及びその使用 |
| US20230151083A1 (en) * | 2020-04-08 | 2023-05-18 | Janssen Biotech, Inc. | Anti-phf-tau antibodies and uses thereof |
| CN116348769A (zh) * | 2020-07-14 | 2023-06-27 | 詹森药业有限公司 | 用于检测tau蛋白病或淀粉样蛋白形成性疾病的基于血液的测定 |
| CA3199806A1 (en) * | 2020-10-26 | 2022-05-05 | Janssen Pharmaceutica Nv | Methods of reducing tau in human subjects |
| WO2022090169A1 (en) * | 2020-10-26 | 2022-05-05 | Janssen Pharmaceutica Nv | Method of safe administration of anti-tau antibody |
| MX2023008317A (es) * | 2021-02-19 | 2023-07-24 | Eisai R&D Man Co Ltd | Anticuerpo anti tau fosforilada en la treonina 217 (pt217). |
| EP4314048A1 (en) | 2021-03-26 | 2024-02-07 | Janssen Biotech, Inc. | Anti-tau antibodies and uses thereof |
| US20250034559A1 (en) | 2021-11-17 | 2025-01-30 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| CN117003863A (zh) * | 2022-04-28 | 2023-11-07 | 厦门大学 | 针对p-tau 217的抗体及其用途 |
| KR20250069606A (ko) | 2022-09-15 | 2025-05-19 | 보이저 테라퓨틱스, 인크. | 타우 결합 화합물 |
| CN116948023B (zh) * | 2023-09-14 | 2024-02-09 | 北京凯祥弘康生物科技有限公司 | Tau蛋白抗体及其应用 |
| CN116948024B (zh) * | 2023-09-14 | 2024-02-06 | 北京凯祥弘康生物科技有限公司 | 抗Tau蛋白的捕获抗体 |
| WO2025122634A1 (en) | 2023-12-05 | 2025-06-12 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| DE69220503T2 (de) | 1991-10-25 | 1998-02-05 | Innogenetics Nv | Monoklonale Antikörper gegen das mikrotubulusassoziierte Protein Tau. |
| ES2270421T3 (es) * | 1993-12-21 | 2007-04-01 | Innogenetics N.V. | Anticuerpos monoclonales especificos para phf-tau, hibridomas que secretan los mismos, reconocimiento de antigeno por estos anticuerpos y sus aplicaciones. |
| WO1996004309A1 (en) | 1994-07-29 | 1996-02-15 | Innogenetics N.V. | Monoclonal antibodies specific for an epitope of a particular subclass or form of phosphorylated tau, hybridomas secreting them, antigen recognition of these antibodies and their applications |
| MXPA05000511A (es) | 2001-07-12 | 2005-09-30 | Jefferson Foote | Anticuepros super humanizados. |
| EP1590369B1 (en) * | 2003-01-24 | 2016-03-16 | Applied Molecular Evolution, Inc. | Human il-1 beta antagonists |
| AU2004297616B2 (en) | 2003-12-04 | 2008-12-18 | Xencor, Inc. | Methods of generating variant proteins with increased host string content and compositions thereof |
| EP1720908A2 (en) | 2004-02-17 | 2006-11-15 | Absalus, Inc. | Super-humanized antibodies against respiratory syncytial virus |
| US20070048785A1 (en) | 2004-06-09 | 2007-03-01 | Lin Laura L | Anti-IL-13 antibodies and complexes |
| EP1790664A1 (en) | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
| CA2659820A1 (en) | 2006-08-04 | 2008-02-14 | Novartis Ag | Ephb3-specific antibody and uses thereof |
| JP2010235447A (ja) | 2007-07-30 | 2010-10-21 | Igaku Seibutsugaku Kenkyusho:Kk | 炎症性サイトカインの抑制剤 |
| JP2012505654A (ja) | 2008-10-14 | 2012-03-08 | ヤンセン バイオテツク，インコーポレーテツド | 抗体をヒト化及び親和性成熟する方法 |
| CA2742969A1 (en) * | 2008-11-07 | 2010-05-14 | Fabrus Llc | Anti-dll4 antibodies and uses thereof |
| US9968574B2 (en) | 2009-05-15 | 2018-05-15 | The University Of Kentucky Research Foundation | Treatment of MCI and Alzheimer's disease |
| CN106390107B (zh) | 2009-06-10 | 2019-12-31 | 纽约大学 | 病理tau蛋白的免疫靶向 |
| US8609097B2 (en) | 2009-06-10 | 2013-12-17 | Hoffmann-La Roche Inc. | Use of an anti-Tau pS422 antibody for the treatment of brain diseases |
| US8912355B2 (en) | 2009-09-29 | 2014-12-16 | University Of Ottawa Heart Institute | Linoleic phospholipids and uses thereof for inhibiting inflammatory and neurodegenerative processes |
| JP2013508287A (ja) | 2009-10-14 | 2013-03-07 | ヤンセン バイオテツク，インコーポレーテツド | 抗体を親和性成熟する方法 |
| MX343227B (es) | 2010-04-09 | 2016-10-28 | Aveo Pharmaceuticals Inc | Anticuerpos anti-erbb3. |
| MY164376A (en) | 2010-10-07 | 2017-12-15 | Univ Leuven Kath | Phosphospecific antibodies recognizing tau |
| CA2813493C (en) * | 2010-10-11 | 2019-07-09 | University Of Zurich | Human anti-tau antibodies |
| MX350311B (es) * | 2011-12-20 | 2017-09-01 | Janssen Biotech Inc | Anticuerpos anti-phf-tau y sus usos. |
-
2018
- 2018-03-15 TW TW107108890A patent/TWI771389B/zh active
- 2018-03-16 US US15/923,011 patent/US10766953B2/en active Active
- 2018-03-16 EP EP18767083.1A patent/EP3596119A4/en active Pending
- 2018-03-16 MA MA047789A patent/MA47789A/fr unknown
- 2018-03-16 JP JP2019549574A patent/JP7159185B2/ja active Active
- 2018-03-16 AU AU2018234709A patent/AU2018234709B2/en active Active
- 2018-03-16 IL IL268700A patent/IL268700B2/en unknown
- 2018-03-16 KR KR1020237037321A patent/KR102695287B1/ko active Active
- 2018-03-16 CN CN202310854848.XA patent/CN117209599A/zh active Pending
- 2018-03-16 CN CN201880018431.7A patent/CN110799531B/zh active Active
- 2018-03-16 AR ARP180100620A patent/AR111288A1/es unknown
- 2018-03-16 CA CA3055598A patent/CA3055598A1/en active Pending
- 2018-03-16 MX MX2019010922A patent/MX2019010922A/es unknown
- 2018-03-16 MY MYPI2019005282A patent/MY205672A/en unknown
- 2018-03-16 KR KR1020197028728A patent/KR102597462B1/ko active Active
- 2018-03-16 WO PCT/US2018/022782 patent/WO2018170351A1/en not_active Ceased
- 2018-03-16 EA EA201992038A patent/EA201992038A1/ru unknown
- 2018-03-16 UY UY0001037635A patent/UY37635A/es not_active Application Discontinuation
- 2018-03-16 SG SG11201907754RA patent/SG11201907754RA/en unknown
- 2018-03-16 IL IL310464A patent/IL310464A/en unknown
- 2018-03-16 UA UAA201910307A patent/UA128385C2/uk unknown
- 2018-03-18 JO JOP/2018/0021A patent/JOP20180021A1/ar unknown
-
2019
- 2019-08-28 PH PH12019501973A patent/PH12019501973A1/en unknown
- 2019-09-09 CL CL2019002566A patent/CL2019002566A1/es unknown
- 2019-09-13 MX MX2024015440A patent/MX2024015440A/es unknown
-
2020
- 2020-08-06 US US16/986,615 patent/US11365244B2/en active Active
-
2021
- 2021-02-26 ZA ZA2021/01318A patent/ZA202101318B/en unknown
-
2022
- 2022-05-18 US US17/747,785 patent/US20230047413A1/en not_active Abandoned
- 2022-10-12 JP JP2022164041A patent/JP2022191383A/ja not_active Withdrawn
-
2023
- 2023-12-12 ZA ZA2023/11412A patent/ZA202311412B/en unknown
-
2024
- 2024-03-29 JP JP2024055230A patent/JP2024088689A/ja not_active Withdrawn
- 2024-07-19 UY UY0001040829A patent/UY40829A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202311412B (en) | Anti-phf-tau antibodies and uses thereof | |
| PH12020552010A1 (en) | Anti-cd33 antibodies, anti-cd33/anti-cd3 bispecific antibodies and uses thereof | |
| PH12021550337A1 (en) | Anti-gdf15 antibodies, compositions and methods of use | |
| ZA202004730B (en) | Anti-claudin 18.2 antibodies and uses thereof | |
| HK1254880A1 (zh) | 抗pd-1抗体及其应用 | |
| PH12019501357A1 (en) | Anti-ox40 antibodies and their uses | |
| HK1255604A1 (zh) | 抗pd-l1抗体及其用途 | |
| PH12018502225A1 (en) | Anti-il-33 antibodies, compositions, methods and uses thereof | |
| PH12019500540A1 (en) | Anti-pd-1 antibodies and their uses | |
| ZA202006318B (en) | Anti-dll3 antibodies and uses thereof | |
| PH12018502456A1 (en) | Anti-cd04 antibodies and their uses | |
| MX2022012749A (es) | Moleculas de union a linfopoyetina estromal timica (tslp) y metodos de uso de las moleculas. | |
| ZA201708265B (en) | Tigit-binding agents and uses thereof | |
| MX2018006973A (es) | Anticuerpos anti-cd73 humanizados. | |
| PH12018502137A1 (en) | Anti-complement factor bb antibodies and uses thereof | |
| PH12022553035A1 (en) | Anti-phf-tau antibodies and uses thereof | |
| PH12020551373A1 (en) | Anti-phf-tau antibodies and uses thereof | |
| MX2021004454A (es) | Anticuerpos anti-sinucleina. | |
| MX2021015766A (es) | Nuevos antigenos y metodos contra el cancer. | |
| ZA201900070B (en) | Antibodies with low immunogenicity and uses thereof | |
| MX2023011339A (es) | Anticuerpos anti-tau y usos de estos. | |
| PH12020550218A1 (en) | MONOCLONAL ANTIBODY TO IL-5Ra | |
| WO2018227063A8 (en) | Anti-robo2 antibodies, compositions, methods and uses thereof | |
| WO2018102594A8 (en) | Methods of treating solid tumors with anti-cd200 antibodies | |
| EA202092121A1 (ru) | Антитела против cd73 и их применения |